AZD0780 + carbamazepine

This is a combination of AZD0780, a novel investigational **oral small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9)** developed for the treatment of hypercholesterolemia, and **carbamazepine**, a well-known **oral small molecule anticonvulsant** also used in bipolar disorder and neuralgias. The combination has been studied in clinical pharmacokinetic drug-drug interaction studies to evaluate the impact of **carbamazepine (a strong CYP3A4 inducer)** on the metabolism and pharmacokinetics of AZD0780, and to assess the potential for clinically significant drug interactions. No clinical programs are pursuing this as a co-formulated or therapeutic combination; rather, the combination is relevant as a tool to study interactions, particularly around hepatic enzyme modulation[1][2][6].

Brand names

TegretolEquetro